Nicolas Gendron: Should Carbon Footprint Influence Therapeutic Decisions?
Nicolas Gendron, Research Fellow and Hematologist at Boston Children’s Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Respiratory Medicine and Research, adding:
”Our editorial has just been published in Respiratory Medicine and Research:
The health 🇫🇷 system accounts for 8 percent of greenhouse gas emissions, of which nearly 40% are related to drugs and medical devices.
Once efficacy and safety are assured, the environmental impact of a treatment becomes a legitimate criterion for clinical decision-making, with therapeutic equivalence.
We illustrate this approach through 2 concrete examples, from recent work:
Oral anticoagulation, by comparing the carbon footprint of 3 direct oral anticoagulants (DOACs) from 2 life 🇪🇺 cycle analysis databases.
Dabigatran emerged as the most carbonaceous DOAC, with an annual footprint of about 124 kg CO2eq, compared to 34 to 37 kg for rivaroxaban and apixaban. This difference is mainly explained by its high daily dose (the active ingredient accounts for nearly 70 percent of its carbon footprint, compared to only 5 to 10 percent for the other two molecules). Another lesson is that reducing the dose of DOACs when clinically indicated reduces the carbon footprint by 5 to 36% over 10 years, depending on the molecule. Study previously published in Haematologica Journal with Laurence Chery Zahra Hassani Lise Durand Dorothee Boisseau Sebastien Taillemite Benjamin de Sainte Marie
Respiratory inhalers, with an analysis of 500 million devices dispensed 🇫🇷 over 10 years.
Pressurised metered-dose inhalers, which account for 44 percent of the total, generated 4.5 MtCO2eq, with a 38.7 percent increase in annual emissions, particularly marked since 2021.
These results argue for systematically integrating the environmental criterion into clinical recommendations when efficacy and safety are comparable.
It’s time to openly measure, document, and discuss the carbon footprint of our therapeutic practices.”
Title: Low-carbon therapeutics in cardiorespiratory medicine: Integrating environmental health into clinical decision-making
Authors: Nicolas Gendron, Victorien Monguillon, David Grimaldi, Maéva Zysman

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series